Abstract Targeted therapies are commonly utilised in modern oncology practice. Skin toxicity is a frequently encountered problem associated with them. Some of the skin toxicites carry prognostic significance and it is important to identify them. Though annoying, treatment interruption is seldom required.
Diagnosis and Discussion
Case 1. Acneiform like rash is the most commonly seen skin reaction caused by EGFR inhibitors like cetuximab. It is usually seen within 4 weeks of treatment. Rash improves with time but complete resolution occurs only after the EGFR inhibitor treatment is completed. Rash is associated with significantly improved disease response rate and overall survival thus serving as a prognostic marker. Clinical benefit from cetuximab and other EGFR inhibitors (panitumumab) is almost always limited to patients experiencing a grade 2 or 3 skin rash. Moreover, absence of rash after the first month of therapy is virtually incompatible with a clinical response from these agents [1] . Case 2. Erlotinib is another EGFR inhibitor used in lung cancer and is associated with a papulo-pustular rash. Rash serves as a surrogate marker for response to treatment and improved overall survival [2] .
Although the rashes are pruritic and painful, they are easily tolerated with the help of topical moisturisers, antiseptics and topical antibiotics and seldom require a brief period of treatment interruption.
